naa a22 4500 510814387 CHVBK 20180411083458.0 cr unu---uuuuu 180411e20130401xx s 000 0 eng 10.1007/s12328-013-0363-4 doi (NATIONALLICENCE)springer-10.1007/s12328-013-0363-4 Nouso Kazuhiro Department of Molecular Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, 700-8558, Okayama, Okayama, Japan aut Current chemotherapies for advanced hepatocellular carcinoma [Elektronische Daten] [Kazuhiro Nouso] The incidence of hepatocellular carcinoma (HCC) increases with the advancement of chronic liver diseases such as hepatitis C or B. The recurrence rate is very high and causes disease progression to an advanced stage. Recent development of molecularly targeted agents for the treatment of advanced HCC has dramatically changed the chemotherapies used for this disease. We summarize the current findings on several drugs that are commonly used for the treatment of advanced HCC including sorafenib and hepatic arterial infusion chemotherapies. Springer Japan, 2013 Hepatocellular carcinoma nationallicence Targeted therapy nationallicence Antineoplastic agents nationallicence Clinical Journal of Gastroenterology Springer Japan 6/2(2013-04-01), 89-93 1865-7257 6:2<89 2013 6 12328 https://doi.org/10.1007/s12328-013-0363-4 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12328-013-0363-4 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Nouso Kazuhiro Department of Molecular Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, 700-8558, Okayama, Okayama, Japan aut NATIONALLICENCE 773 0- Clinical Journal of Gastroenterology Springer Japan 6/2(2013-04-01), 89-93 1865-7257 6:2<89 2013 6 12328 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer